Floatz logo

Chir-258

Glucagonoma

Academic and Community Cancer Research UnitedPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Glucagonoma cohort.

Asset / SponsorPhaseRating
Capecitabine
Vanderbilt-Ingram Cancer Center
Phase 2BB
Eloxatin
Vanderbilt-Ingram Cancer Center
Phase 2BB
Irinotecan
Shaheen Shagufta
Phase 2B
(+)-VINCRISTINE
Shaheen Shagufta
Phase 2B
Everolimus
Emory University
Phase 2B

View all 14 →

Same molecule, other indications

Chir-258 is also rated in:

NeoplasmsDormant
B
Indicative ·
57 / 100
View asset →
Stage III Pancreatic CancerDormant
CCC
Indicative ·
54 / 100
View asset →
Breast CancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →